FDA Approves STEGLATRO — Merck Sharp & Dohme LLC

# FDA Approves Merck's STEGLATRO (Ertugliflozin) for Type 2 Diabetes Merck Sharp & Dohme LLC received FDA approval for STEGLATRO (ertugliflozin), an oral SGLT2 inhibitor, positioning the company to compete in the rapidly expanding diabetes treatment market against established players like Johnson & Johnson's INVOKANA and AstraZeneca's FORXIGA. The approval expands Merck's diabetes portfolio and adds a new revenue stream in a competitive therapeutic class with significant growth potential among